Vivesto AB (STO:VIVE)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0810
0.00 (0.00%)
May 6, 2026, 5:29 PM CET
Market Cap89.68M -29.2%
Revenue (ttm)n/a
Net Income-34.08M
EPS-0.06
Shares Out1.11B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume829,654
Average Volume740,274
Open0.0820
Previous Close0.0810
Day's Range0.0810 - 0.0840
52-Week Range0.0700 - 0.3190
Beta0.82
RSI49.26
Earnings DateMay 13, 2026

About Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR... [Read more]

Sector Healthcare
Founded 1988
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol VIVE
Full Company Profile

Financial Performance

Financial Statements